伊布替尼致重度肝损害1例附文献分析

摘要/Abstract

摘要： 目的：探讨伊布替尼导致肝损害的临床特征并分析伊布替尼导致肝损害的特点及可能机制，以期为临床合理用药提供参考。方法：基于我院1例患者应用伊布替尼治疗滤泡细胞淋巴瘤过程中出现严重胆汁淤积性肝损害的案例，综合分析患者服用伊布替尼后出现肝损害后相关指标变化，并结合国内外伊布替尼引起肝损害的案例报道分析，探讨伊布替尼导致肝损害的特点及可能机制。结果：本例患者服用伊布替尼72 d后出现胆红素、胆汁酸和转氨酶上升，彩超提示弥漫性肝损害。结论：伊布替尼服用后虽然很少出现因药物不良反应停药现象，但可能在肝脏中蓄积，进而导致肝损害的发生。建议临床上使用伊布替尼时，检测肝功能尤为必要，特别是对于基线时肝功能就出现异常的患者。

关键词: font-size:medium, ">伊布替尼；药物性肝损害；胆汁淤积

Abstract: Objective：To investigate the clinical features of ibrutinib-induced liver injury and to analyze its characteristics and possible pathogenesis. Methods：Based on a case of severe cholestatic liver injury in a patient with follicular cell lymphoma treated with ibrutinib，the changes in relevant indicators of liver injury after taking ibrutinib were comprehensive analyzed，and combined with the case report of liver injury cause by ibrutinib at home and abroad， to investigate the characteristics and possible mechanism of ibrutinib-induced liver injury. Results：The patient showed an increase in bilirubin， bile acid and transaminase 72 d after taking ibrutinib. Doppler ultrasonography image showed diffuse liver damage. Conclusion：Although the withdrawal of ibrutinib due to side effects is rare， it may accumulate in the liver and lead to liver injury.It is suggested that it is necessary to detect liver function when using ibrutinib clinically，especially in patients with abnormal liver function at baseline.

Key words: font-size:medium, ">Ibrutinib； Drug-induced liver injury；Cholestasis

中图分类号:

朱鸿斌, 卫延辉, 林晓燕, 何玉卓, 郭学军, 刘正彪. 伊布替尼致重度肝损害1例附文献分析[J]. 中国医药导刊, 2023, 25(1): 110-113.

ZHU Hongbin, WEI Yanhui, LIN Xiaoyan, HE Yuzhuo, GUO Xuejun, LIU Zhengbiao. Severe Liver Injury Caused by Ibrutinib Case Report and Literature Analysis[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2023, 25(1): 110-113.

参考文献

[1]Davids MS，Brown JR. Ibrutinib： a first in class covalent inhibitor of Bruton′s tyrosine kinase[J]. Future Oncol， 2014， 10（6）： 957-967.
     [2]Wang ML， Rule S， Martin Peter， et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med， 2013， 369（6）： 507-516.
     [3]O′Brien S，Furman RR，Coutre SE， et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma： an open-label， multicentre， phase 1b/2 trial[J]. Lancet Oncol， 2014， 15（1）： 48-58.
     [4]O′Brien S，Hillmen P，Coutre S， et al. Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma or mantle cell lymphoma[J]. Clin Lymphoma Myeloma Leuk，2018，18(10)： 648-657.
     [5]Tafesh ZH，Coleman M，Fulmer C，et al. Severe hepatotoxicity due to ibrutinib with a review of published cases[J] .Case Rep Gastroenterol，2019，13(2)： 357-363.
     [6]Nandikolla AG，Derman O，Nautsch D， et al. Ibrutinib-induced severe liver injury[J].Clin Case Rep， 2017， 5(6)： 735-738.
     [7]Kleijwegt FS，Roda AA，Rolvink J， et al. Rare but serious： ibrutinib induced liver failure[J].Hemasphere，2019， 3(6)： e307.
     [8]Kahn A，Horsley-Silva JL，Lam-Himlin DM，et al. Ibrutinib-induced acute liver failure[J].Leuk Lymphoma， 2018，59(2)： 512-514.
     [9]Honigberg LA， Smith AM， Sirisawad M，et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy[J].Proc Natl Acad Sci USA，2010，107(29)：13075-13080.
     [10]Ponader S， Chen SS， Buggy JJ，et al. The bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo[J].Blood，2012，119(5)：1182-1189.
     [11]Wilson WH，Young RM，Schmitz R，et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma[J].Nat Med，2015，21(8)： 922-926.
     [12]Herman SE，Gordon AL，Hertlein E，et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765[J].Blood，2011，117(23)： 6287-6296.
     [13]de Weerdt I，Koopmans SM，Kater AP， et al. Incidence and management of toxicity associated with ibrutinib and idelalisib：a practical approach[J]. Haematologica，2017，102(10)： 1629-1639.
     [14]Fontana RJ，Watkins PB，Bonkovsky H， et al.Drug-induced liver injury network (DILIN) prospective study： rationale， design and conduct[J].Drug Saf，2009，32(1)：55-68.
     [15]Shah RR，Morganroth J，Shah DR. Hepatotoxicity of tyrosine kinase inhibitors： clinical and regulatory perspectives[J].Drug Saf，2013，36(7)：491-503.
     [16]Juurlink DN，Drug-induced hepatotoxicity[J].N Engl J Med，2003，349(20)：1974-1976.
     [17]WHO global pharmacovigilance center[EB/OL].[2022-10-10].http：//www.vigiaccess.org.

快速检索引用检索图表检索高级检索